Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Job Board

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Spanning across the United Kingdom, the United States, European Union, and Japan, the global phase 3 EMPEROR study of zorevunersen is expected to have data readout by the end of 2027.

Analyzing Zorevunersen in Phase 3 Registrational Study for Dravet Syndrome: The EMPEROR Trial

Serum NPTX2 emerges as a novel biomarker in ALS, with combined NPTX2 and NfL levels improving survival prediction and disease monitoring.

NPTX2 Identified as Synaptic Biomarker Implicated in ALS Survival, Disease Progression

Regeneron's cemdisiran shows promising results in treating generalized myasthenia gravis, paving the way for a potential new drug application in 2026.

Regeneron to Submit Application for Cemdisiran in Myasthenia Gravis Following Positive Phase 3 NIMBLE Data

Videos

The director of the Norman Fixel Institute for Neurological Diseases at UF Health highlighted the need for equitable, worldwide access to levodopa for patients with Parkinson disease. [WATCH TIME: 6 minutes]

A Global Calling for Universal Levodopa Access in Parkinson Disease Treatment: Michael S. Okun, MD

The neurologist at Maimonides Medical Center and SUNY Downstate shared how interactive simulations give neurology trainees the chance to practice skills, gain feedback, and move beyond passive learning. [WATCH TIME: 3 minutes]

Clinical and Educational Advantages of Simulations in Training the Next Generation of Neurologists: Nuri Jacoby, MD

, has been with the team since September 2022. Follow her on Twitter 

Experts shared their clinical perspectives on trending topics in the treatment and management of movement disorders at the 4th Annual Advanced Therapeutics in Movement and Related Disorders (ATMRD) Congress.


ATMRD Congress 2025: Top Expert Interviews and Key Takeaways

Patient advocate living with PD and advisory board member of the Parkinson's Foundation. 

At the 2025 ATMRD Congress, a patient advocate living with Parkinson disease emphasized the importance of amplifying patient voices at educational conferences for movement disorders. [WATCH TIME: 5 minutes]

Elevating Patient Perspectives in the Mangement of Parkinson Disease: Esther Labib-Kiyarash, MSHA, CPHQ

Associate professor, Ferkauf Graduate School of Psychology, Yeshiva University, and associate professor, department of neurology, Albert Einstein College of Medicine.

At AHS 2025, Elizabeth Seng, PhD, professor of neurology at Albert Einstein College of Medicine, presented findings from a study showing that migraine was associated with increased odds of ischemic stroke in veterans.

Analyzing How Sex and Age May Influence Risk of Stroke in Veterans With Migraine

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

Anti-epileptics in Pregnancy?

Newsletter